Efficacy of Topical Tyrosine Versus Topical 5-Fluorouracil With Fractional Erbium YAG Laser

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorAswan University

About this trial

Vitiligo is an autoimmune disorder affecting the skin, specifically targeting pigment-producing melanocytes, leading to noticeable regions of depigmentation characterized by white spots.

It is a widely prevalent skin disorder globally, affecting males and females almost equally, although it is reported slightly more frequently in females. In more than 60% of patients, the disease begins before the age of 30 and It has an estimated prevalence of roughly 0.2-2% across various populations, with around 0.4% in the European-derived white (EUR) population.

Eligibility criteria

Qualifiers

None

Disqualifiers

Pregnancy.

Lactation.

Patients with segmental vitiligo.

Patients with autoimmune disease including thyroiditis.

Trial design

Treatments tested in this trial

  • Tyrosine

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators